Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 20/20 | 0.59 |
| ▸ | JAK2 | O60674 | 1/20 | 0.56 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.56 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.56 |
| ▸ | TTK | P33981 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4079437 | 0.92 | LRRK2 (0.55) | LRRK2 | |
| SCHEMBL1203596 | 0.89 | GSK3A (0.58) | LRRK2 | |
| SCHEMBL3672295 | 0.88 | PLK1 (0.57) | LRRK2TTK | |
| SCHEMBL3667130 | 0.85 | GSK3A (0.52) | LRRK2TTK | |
| SCHEMBL4080991 | 0.85 | LRRK2 (0.62) | LRRK2JAK2MAP3K9MKNK2 | |
| SCHEMBL3668298 | 0.84 | PLK1 (0.54) | LRRK2 | |
| SCHEMBL1203143 | 0.82 | PLK1 (0.66) | LRRK2 | |
| SCHEMBL616764 | 0.80 | TNK2 (0.67) | LRRK2 | |
| SCHEMBL4079432 | 0.79 | PLK1 (0.63) | LRRK2 | |
| SCHEMBL16065750 | 0.76 | NUAK1 (0.82) | LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517873-B2 | Substituted pyrimidodiazepines | HOFFMAN-LA ROCHE INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20080234255-A1 | SUBSTITUTED PYRIMIDODIAZEPINES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234255-A1 | SUBSTITUTED PYRIMIDODIAZEPINES | PLK1, CCNI, CDK1 | LRRK2 485/4885JAK2 284/4885MAP3K9 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.